News

In Italy, people with hereditary angioedema (HAE) types 1 or 2 are not at an increased risk of premature death relative to the general population, and swelling that blocks the airway is not the main cause of death, a new study has found. The study, “Life…

The gleaming new Dutch headquarters of the European Medicines Agency (EMA), fronting Domenico Scarlattilaan in Amsterdam’s suburban Zuidas business district, finally opened for business last month — just over two years after the European Union decided to relocate the EMA to the Netherlands in the wake of Brexit.

BioCryst Pharmaceuticals has submitted an application to the Japanese regulatory authority asking that oral berotralstat (BCX7353) be approved for the prevention of swelling attacks in people with hereditary angioedema (HAE). The new drug application (NDA), submitted to the Pharmaceuticals and Medical Devices Agency (PMDA) in Japan, follows…

The European Medicines Agency (EMA) has approved a type II variation for a new facility to produce Ruconest (conestat alfa), Pharming’s lead therapy for acute attacks in hereditary angioedema (HAE). The new facility is expected to be fully operational by 2021 and to increase the production…

A new diagnostic tool has been identified for people with hereditary angiodema (HAE) and normal C1 inhibitor activity, potentially establishing the first method that doctors can use to properly diagnose this genetic condition, a study suggests. The study, “sgp120 and the contact system in hereditary…

Researchers have developed a new tool that measures disease activity specifically in people with hereditary angioedema due to C1-inhibitor deficiency (C1-INH-HAE), which could prove useful in the medical care of patients and for assessing outcomes in clinical trials. The Hereditary Angioedema Activity Score (HAE-AS) was described in the…

Use of ACE inhibitors to treat high blood pressure can sometimes cause swelling (angioedema) episodes, but the prevalence of this potentially life-threatening side effect is not well-known because it is rarely reported, a Danish study into a “drug reaction” database found. The study, “ACE-Inhibitor Related Angioedema Is…

Results of the Phase 2 clinical trial testing KalVista Pharmaceuticals‘ oral investigational therapy KVD900 as an on-demand treatment for hereditary angioedema (HAE) attacks will be announced by August. The company also announced it has selected KVD824 as an oral preventive therapy for HAE. A Phase 2…

Researchers have identified risk factors that may predispose children to more severe initial angioedema attacks — factors such as male gender, preschool age, presence of fever or hives, and a history of allergies. Epinephrine treatment and receiving care in a pediatric observation unit, on the other hand, were factors that…

Researchers developed a questionnaire, called the Angioedema Control Test (AECT), that may be helpful in monitoring disease control and patient-reported outcomes among people with recurrent angioedema. The tool is described in the journal Allergy, in the study, “Development of the Angioedema Control Test (AECT) – A Patient…